FKFawad Ahmed Khan

Fawad Ahmed Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fawad Ahmed Khan has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Isolated Eyelid Elevation From Partial Oculomotor Nerve Activation During Stereoencephalography

    by Fawad A. Khan, Parth C. Patel, Colin N. Curtis

    Was not provided for this article.

  • Open Access

    Defining the end point of status epilepticus: A scoping review and framework for standardization

    by Fawad A. Khan, Margaret T. Gopaul, Samuel L. Carter, Anil Chimakurthy, Summer Skelton, Lawrence J. Hirsch, Eugen Trinka

    Status epilepticus (SE) is a life‐threatening neurological emergency with consensus‐driven definitions for onset but no standardized criteria for its end point. This gap creates uncertainty in research and clinical practice. We conducted a scoping review to evaluate how end points have been defined in SE research and to identify key areas of variability. Comprehensive searches of MEDLINE, Embase, and CENTRAL (Cochrane Central Registry of Controlled Trials; 1980–2025) yielded 3940 citations (1674 unique). After screening, 207 studies met the inclusion criteria and were charted using scoping review methodology (Preferred Reporting Items of Systematic Reviews and Meta‐Analyses, extension for scoping reviews). Data were extracted on terminology, electroencephalography (EEG) use, temporal thresholds, and definitions of therapeutic success across retrospective and prospective designs. Five domains of heterogeneity were identified: (1) semantic terminology (e.g., “resolved,” “controlled,” “terminated,” “cessation”); (2) EEG confirmation of the SE end point (reported in 54% of studies, with variable criteria); (3) whether time was included in defining the end point; (4) how quickly seizures were judged to have stopped, based on clinical signs, EEG findings, or both; and (5) how long seizure freedom had to be maintained to count as a successful end point. No consistent global or time‐based patterns were identified, and overlapping terminology further limited comparison across studies. Despite established consensus definitions for SE onset, the end point remains variably defined, undermining methodological rigor and limiting cross‐study synthesis. A unified, consensus‐driven framework is urgently needed to standardize SE end points through the use of standard terminology and methodologies, thereby strengthening clinical trial design and facilitating regulatory evaluation of novel therapies.


  • Professional medical associations as catalytic pathways for advancing women in academic medicine and promoting leadership

    by Fawad A. Khan, Margaret T. Gopaul, Elizabeth J. Howard, Jennifer Robblee, Ann H. Tilton, Margot Savoy

  • Open Access

    Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine

    by Fawad A. Khan, Steven P. Herzog, Ryan M. Smith, Dawn C. Buse, Seema Soni-Brahmbhatt, Susanne F. Awad, S. Wald Grossman, Divya Asher, Foram Patel, Charles Argoff

    Background: Data from the real-world REVIEW (Real-world EVidence and Insights into Experiences With eptinezumab) study demonstrated that, after starting treatment with eptinezumab, individuals with chronic migraine (CM) experienced double the number of good days per month and high rates of satisfaction with eptinezumab. This post-hoc analysis explored the associations between self-reported changes in good days per month and other health-related outcome measures and the utility of good days per month as a patient-centric measure of the composite impact of migraine and migraine treatment on an individual. Methods: REVIEW was an observational, multi-site study designed to evaluate real-world experiences of patients treated with eptinezumab. A survey was administered to adults with CM who had completed ≥ 2 treatment cycles with eptinezumab. These post hoc analyses evaluated the impact of eptinezumab treatment on the ability to achieve a ≥ 50% and ≥ 75% increase in self-reported good days per month, and the association between these improvements and migraine symptoms, elements of daily living, overall well-being, and brain fog. Results are reported for the subgroups defined by the percentage change in self-reported good days per month after initiating eptinezumab treatment relative to before initiation (≥ 75% increase vs. < 75% and ≥ 50% increase vs. < 50%). Results: Following eptinezumab initiation, ≥ 75% and ≥ 50% increases in good days per month were reported by 59/92 (64%) and 70/92 (76%) evaluable participants, respectively. Participants with ≥ 75% increase in good days per month also reported a greater positive impact on multiple migraine symptom domains (68%–90%), as well as select aspects of daily living and overall well-being (73%–90%) compared with participants with < 75% increase (27%–61% and 18%–39%, respectively). Moderate to complete improvement in brain fog after eptinezumab was reported by 77% of participants in the ≥ 75% increase subgroup versus 42% in the < 75% subgroup. Results were consistent for the ≥ 50% increase versus < 50% subgroups. Conclusions: Following eptinezumab treatment, most participants reported substantial increases in good days per month, with those experiencing ≥ 75% improvement also reporting greater improvements across multiple migraine symptom domains, daily functioning, overall well-being, and brain fog. These real-world data underscore the importance of novel, patient-centered approaches to understand how preventive therapies can reduce multiple aspects of migraine burden. Trial registration: N/A.


  • Open Access

    Permanent visual impairment following a Behçet’s disease flare while on calcitonin gene-related peptide receptor antagonist therapy: a case report

    by Fawad A. Khan, Alaa Malik, Evan Nelson, Kian Fahimdanesh, Karmveer Kaur, Jasmine Elison, Mohamed Sayed

    Background: Behçet’s disease (BD) is a chronic, relapsing, systemic vasculitis that can involve both arteries and veins. Ocular involvement, including non-granulomatous panuveitis and occlusive retinal vasculitis, is common and a significant cause of morbidity. Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor approved for migraine prevention Although it is generally well tolerated, recent concerns have emerged regarding its vasoconstrictive potential in patients with underlying vascular disorders. Case presentation: We report a case of a 44-year-old woman with a history of BD, well-managed with azathioprine and methotrexate, who developed painless, bilateral subacute visual loss eleven days after receiving her second monthly dose of erenumab. This occurred during a BD flare marked by oral ulcers and severe migraine. Despite corticosteroid treatment, visual acuity did not improve. Erenumab was discontinued, but at her following visit four weeks later, vision remained impaired and visual fields showed blind spot enlargement and nonspecific defects. Conclusion: We hypothesize that the patient’s visual loss was due to secondary ischemia from BD–associated small-vessel vasculitis, potentially exacerbated by CGRP receptor blockade from erenumab, which may have impaired compensatory vasodilation in the optic nerve or retinal circulation. This case represents the first report of permanent bilateral visual impairment associated with CGRP antagonist use in a patient with BD. Recent FDA labeling updates for CGRP-targeting agents now caution against use in patients with preexisting vascular disease, including risk of hypertension and Raynaud’s phenomenon. This case underscores the need for heightened caution when prescribing CGRP inhibitors to patients with systemic vasculitic disorders and highlights the importance of further investigation to better define the safety profile of these agents in individuals with underlying vascular disease.


  • Open Access

    Reaching international consensus on the definition of refractory migraine using the Delphi method

    by Jennifer Robblee, Fawad A. Khan, Michael J. Marmura, Hope L. O’bRien, Lawrence D. Robbins, Marielle Kabbouche Samaha, Morris Levin, Simona Sacco, Raffaele Ornello, Stephanie J. Nahas, et al.

    Aim: Despite its frequency in tertiary headache centers, the International Classification of Headache Disorders, 3rd edition (ICHD-3) does not include refractory migraine. Multiple definitions have been proposed with a recent 2020 proposal for both refractory migraine and resistant migraine by the European Headache Federation (EHF). The aim is to reach an international consensus on the definition of refractory migraine. Methods: This study is a Delphi consensus carried out by a group of international experts in headache medicine. Following a focus group, a panel of 20 experts and one facilitator reviewed the EHF proposed criteria to build upon their definitions. The Delphi consensus was conducted across five rounds. Questions with >70% consensus were deemed to have strong agreement, 60–70% consensus was deemed minor agreement, and <60% deemed no agreement. A final meeting was held to discuss any concerns and specific wording. Results: The Delphi consensus led to the development of four key categories: refractory migraine, probable refractory migraine, resistant migraine, and treatment-responsive migraine. Similar to the EHF 2020 definitions, refractory migraine requires treatment failure of all evidence-based classes, and resistant migraine requires failure of at least three classes. Probable refractory migraine criteria were designed to account for situations where treatment access barriers may prevent trials of certain medication classes (e.g. pediatrics, low to middle-income countries, lack of insurance coverage). Finally, treatment-responsive migraine criteria were developed to allow for standardization in research studies comparing refractory or resistant migraine to migraine that is treatment-responsive. Conclusions: These four categories may aid in enrollment for studies on pathophysiology, biomarkers, and new treatment targets. Clinically, the criteria for refractory and resistant migraine will help with clinical decision-making by reinforcing the need to try evidence-based treatments and by providing guidance regarding when to try more aggressive treatment approaches. These criteria may also increase attention to this population's disease burden to help advocate for them as a specific migraine subgroup. Field testing in diverse clinical settings will be needed, but it is recommended that ICHD-3 considers inclusion of these four categories in their appendix.


  • Person-Directed Ictal Pointing Gesture During a Focal Seizure

    by Fawad Khan, Evan Nelson, Colin Curtis


  • Complete ophthalmoplegia secondary to idiopathic intracranial hypertension managed successfully with dural sinus stenting: A case and systematic review

    by Mansour Mathkour, Tyler Scullen, Mitchell D. Kilgore, Edna E. Gouveia, Julie Chu, Hussam Abou-Al-Shaar, R. Shane Tubbs, Fawad Khan, Cuong J. Bui